MYL Stock: Mind the Gap
Mylan N.V. (NASDAQ: MYL) stock is rocketing higher on the heels of a U.S. Food and Drug Administration (FDA) approval of its glatiramer acetate injection. This is a generic drug that is used to treat multiple sclerosis, and it is expected to begin shipping immediately. Investors are completely enamored with the news, and they have responded by pushing the MYL stock price higher by 16.2%.
This surge in price did quite a number on the Mylan stock chart, and for someone like myself, who analyzes investments using the company's stock chart, it definitely piqued my interest.
If this is the first time you are coming across one of my.
Den vollständigen Artikel lesen ...
Mylan N.V. (NASDAQ: MYL) stock is rocketing higher on the heels of a U.S. Food and Drug Administration (FDA) approval of its glatiramer acetate injection. This is a generic drug that is used to treat multiple sclerosis, and it is expected to begin shipping immediately. Investors are completely enamored with the news, and they have responded by pushing the MYL stock price higher by 16.2%.
This surge in price did quite a number on the Mylan stock chart, and for someone like myself, who analyzes investments using the company's stock chart, it definitely piqued my interest.
If this is the first time you are coming across one of my.
Den vollständigen Artikel lesen ...